Hermetica Superfood Encyclopedia
The Short Answer
Chacruna leaves contain N,N-dimethyltryptamine (DMT), an indole alkaloid that acts as a potent agonist at serotonin 5-HT2A receptors, producing hallucinogenic effects when oral MAO inhibition is provided by a co-administered beta-carboline source. In vitro studies demonstrate that chloroform and ethyl acetate leaf extracts inhibit acetylcholinesterase by greater than 90%, and DMT alongside related extracts selectively induces cytotoxicity in B16F10 and 4T1 tumor cell lines at concentrations of 20–400 µg/mL without apparent harm to normal BHK and CHO cells, though no human clinical trials have evaluated these effects in isolation.
CategoryHerb
GroupAmazonian
Evidence LevelPreliminary
Primary Keywordchacruna benefits
Chacruna — botanical close-up
Health Benefits
**Serotonergic Modulation (via DMT)**
DMT binds with high affinity to 5-HT2A receptors in cortical regions, producing altered states of consciousness that, within structured ayahuasca contexts, have been associated in observational studies with reductions in depressive and anxious symptomatology, though P. viridis has not been isolated as the sole therapeutic variable.
**Acetylcholinesterase Inhibition**: Chloroform and ethyl acetate extracts of P
viridis leaves inhibit acetylcholinesterase activity by over 90% in vitro, an effect attributed partly to 24-methylene-cycloartanol and glycosylated sitosterols, suggesting a potential neuroprotective or pro-cognitive mechanism analogous to pharmaceutical AChE inhibitors.
**Selective Antitumor Activity (Preclinical)**
Leaf extracts and isolated DMT exhibit selective cytotoxicity against murine melanoma (B16F10) and breast cancer (4T1) cell lines at 20–400 µg/mL, while sparing normal BHK and CHO cells, with the mechanism likely involving apoptosis induction, though this has not been replicated in animal or human models.
**Antioxidant Activity**
Ultrasound-assisted extraction of leaves yields total phenolic content of 20.75–45.73 mg GAE/g dry matter, with ABTS radical scavenging activity of 422–939 µmol TE/g and DPPH activity of 276–547 µmol TE/g, driven by phenolic compounds exhibiting a Pearson correlation coefficient of 0.93–0.97 with antioxidant capacity.
**Anti-inflammatory Potential (Phytosterol Content)**
Leaves contain β-sitosterol, stigmasterol, and their glucosylated derivatives, compounds documented in other botanical contexts to modulate NF-κB signaling and inhibit pro-inflammatory prostaglandin synthesis, though this has not been specifically tested in P. viridis models.
**Spiritual and Psychological Healing (Traditional Context)**: Within traditional Amazonian medicine, the ayahuasca brew containing P. viridis is used to address psychological trauma, grief, and addiction; modern observational studies of ayahuasca ceremonies report self-reported improvements in well-being and meaning-making, though attribution to P. viridis alone is confounded by the multi-ingredient preparation.
Origin & History
Natural habitat
Psychotria viridis is native to the tropical rainforests of the Amazon Basin, distributed across Peru, Brazil, Ecuador, Colombia, and Bolivia, where it grows as a perennial shrub in humid understory environments at low to mid elevations. It is cultivated by Indigenous Amazonian communities—including the Shipibo, Asháninka, and related groups—specifically for ceremonial use, typically planted near villages or in managed garden plots rather than harvested exclusively from wild populations. The plant thrives in rich, well-drained forest soils under partial shade, reaching 2–5 meters in height, with glossy dark-green leaves that concentrate the highest alkaloid content when mature.
“Psychotria viridis has been integral to the spiritual and healing practices of numerous Amazonian Indigenous peoples—including the Shipibo-Conibo, Asháninka, Yawanapi, and Tukano—for centuries, possibly millennia, under the name 'chacruna' (from the Quechua 'chaqruy,' meaning 'to mix'), reflecting its role as the visionary admixture added to the B. caapi vine base of ayahuasca. The plant is regarded as a 'plant teacher' or 'plant spirit' in many Amazonian cosmologies, with ceremonial use directed by trained healers called curanderos or ayahuasceros who employ the brew for spiritual diagnostics, community healing, treatment of psychological illness, and communication with ancestral spirits. Preparation methods have been transmitted orally across generations and vary regionally in the ratio of P. viridis leaves to B. caapi vine, decoction time, and supplementary admixture plants; the synergistic pharmacological basis of this pairing—DMT plus MAOI—was not understood scientifically until the mid-20th century, when ethnobotanists including Richard Evans Schultes and later Luis Eduardo Luna documented and analyzed these traditions. The global expansion of ayahuasca use into Western therapeutic and neoshamanic contexts during the late 20th and early 21st centuries has elevated P. viridis from a regionally specific sacred plant to a subject of neuroscientific, psychiatric, and legal inquiry worldwide.”Traditional Medicine
Scientific Research
The evidence base for P. viridis as an isolated ingredient is limited exclusively to in vitro and phytochemical studies; no randomized controlled trials, animal pharmacology studies, or clinical trials have been published evaluating P. viridis leaf extracts or DMT from this source in human subjects as a standalone intervention. Published in vitro data demonstrate greater than 90% acetylcholinesterase inhibition by chloroform and ethyl acetate extracts, selective tumor cell cytotoxicity at 20–400 µg/mL across two murine cancer cell lines, and quantified antioxidant capacity across ultrasound-assisted extraction conditions (20.75–45.73 mg GAE/g TPC), but none of these studies report sample sizes, confidence intervals, or reproducibility across independent laboratories. Research on ayahuasca as a combined preparation includes observational studies and a small number of open-label trials examining mood, depression, and anxiety outcomes, but these do not isolate P. viridis from B. caapi or other co-ingredients, making it impossible to attribute outcomes to chacruna specifically. Forensic and phytochemical characterization studies have described alkaloid profiles in dried and fresh leaf material, highlighting variability in DMT content, but standardized quantification across botanical sources remains absent from the peer-reviewed literature.
Preparation & Dosage
Traditional preparation
**Traditional Ayahuasca Brew**
50–150 g per person) are combined with B
Fresh or dried P. viridis leaves (typically . caapi vine stem segments and boiled in water for 4–12+ hours in repeated reduction cycles; the resulting decoction contains variable DMT and beta-carboline concentrations depending on plant material quality and preparation technique.
**Dried Leaf Material (Ethnobotanical Supply)**
Commercially available dried chacruna leaves are used by practitioners for home brew preparation; no standardized alkaloid content per gram is established, and DMT concentrations vary considerably across geographic sources and harvest conditions.
**Leaf Extracts (Research Context)**
Laboratory extractions use hexane, chloroform, methanol, or ethyl acetate as solvents to isolate specific compound classes; these are not available as commercial supplements and exist only in research settings.
**No Established Therapeutic Dose**
1 mg/kg from B
There is no clinically validated supplemental dosage for P. viridis as an isolated ingredient; DMT from this source is pharmacologically inactive by the oral route without concurrent MAO inhibition (minimum effective inhibition typically requires harmine ≥. caapi).
**Standardization Status**
No commercial standardized extracts of P. viridis are available; no pharmacopoeial monographs exist for this plant material outside of traditional or ceremonial frameworks.
Nutritional Profile
Psychotria viridis leaves are not used as a nutritional food source, and no comprehensive macronutrient or micronutrient analysis has been published. Phytochemically, leaves contain indole alkaloids (primarily DMT and N-methyltryptamine at variable but pharmacologically relevant concentrations), pentacyclic triterpenes (ursolic acid and oleanolic acid), phytosterols (β-sitosterol, stigmasterol, 24-methylene-cycloartanol), their glucosylated conjugates (3-O-β-D-glucosyl-β-sitosterol, 3-O-β-D-glucosyl-stigmasterol), squalene, glycerol esters (1-palmitoylglycerol, triacylglycerols), long-chain hydrocarbons (nonacosanal), and fatty acids including hexadecanoic (palmitic), heptadecenoic, and hentriacontanoic acids. Total phenolic content measured by ultrasound-assisted extraction ranges from 20.75 to 45.73 mg GAE per gram of dry leaf matter, with antioxidant capacity in the moderate-to-high range relative to other botanical sources. Bioavailability of DMT via oral consumption is negligible without concurrent MAO inhibition; phytosterol bioavailability would depend on fat co-ingestion, and triterpene absorption from leaf material without standardized extraction is expected to be low.
How It Works
Mechanism of Action
DMT, the principal psychoactive alkaloid in P. viridis leaves, acts as a full or partial agonist at 5-HT2A serotonin receptors in prefrontal cortical neurons, initiating downstream signaling through Gq/11 protein pathways, phospholipase C activation, and inositol trisphosphate-mediated intracellular calcium release, culminating in altered thalamocortical information gating and the hallucinogenic state; this mechanism is functionally inactive via oral route unless monoamine oxidase (MAO-A) is inhibited, as endogenous MAO rapidly deaminates DMT in the gut and liver. Leaf extracts also demonstrate robust acetylcholinesterase inhibition exceeding 90% in vitro, attributed to triterpenoids such as ursolic and oleanolic acid and glycosylated phytosterols (3-O-β-D-glucosyl-β-sitosterol), which may competitively or non-competitively bind the enzyme's active or peripheral anionic sites, thereby increasing acetylcholine availability at cholinergic synapses. The selective cytotoxic effect observed in tumor cell lines is hypothesized to involve mitochondrial pathway apoptosis, consistent with DMT's known interaction with sigma-1 receptors (Sig-1R), intracellular chaperone receptors enriched in cancer cells that regulate ER stress responses and cell survival; phenolic constituents provide complementary antioxidant activity by donating hydrogen atoms to quench reactive oxygen species.
Clinical Evidence
No clinical trials have been conducted specifically on Psychotria viridis leaf extracts or isolated DMT derived from this plant in human participants as a defined therapeutic intervention. Available data from ayahuasca ceremony observational studies and a handful of open-label pilot trials suggest potential antidepressant and anxiolytic effects of the combined brew, but effect sizes and confidence intervals are not attributable to P. viridis in isolation due to the multi-ingredient nature of the preparation. In vitro cytotoxicity and enzyme inhibition data are hypothesis-generating at best, lacking the in vivo pharmacokinetic context, dose-response validation, and replication needed to establish clinical relevance. Overall confidence in any therapeutic claim for P. viridis as a standalone ingredient is very low, and all mechanistic insights currently exist at the preclinical stage without human translational evidence.
Safety & Interactions
Psychotria viridis has no established safety profile as an isolated supplement in humans; the primary safety data derive from ayahuasca ceremony contexts, where acute effects of DMT-containing brews include nausea, vomiting (the 'purge' considered therapeutically significant in traditional use), transient hypertension, tachycardia, mydriasis, anxiety, and psychological distress including acute psychotic episodes in vulnerable individuals. The most critical drug interaction risk involves serotonin syndrome when DMT (from P. viridis) is combined with serotonergic pharmaceuticals, particularly SSRIs, SNRIs, TCAs, lithium, triptans, or prescribed MAOIs; concurrent use of these agents with any ayahuasca preparation containing P. viridis is contraindicated and potentially life-threatening. Absolute contraindications include personal or family history of psychosis or schizophrenia spectrum disorders, active cardiovascular disease or poorly controlled hypertension, pregnancy and lactation (DMT crosses the placental barrier and no fetal safety data exist), and severe hepatic impairment. No maximum safe dose has been established for isolated P. viridis extracts; DMT is a Schedule I controlled substance in the United States and many other jurisdictions, and P. viridis itself is regulated or controlled in several countries due to its DMT content, with significant legal and forensic implications for possession and use.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
chacrunaTupamaqui (Psychotria viridis)wild coffee leafPsychotria viridisamirucasami ruca
Frequently Asked Questions
What is chacruna used for in ayahuasca?
Chacruna (P. viridis) is the primary DMT-containing ingredient in ayahuasca, providing the psychoactive alkaloid N,N-dimethyltryptamine that activates serotonin 5-HT2A receptors to produce visionary states. Without the MAO-inhibiting beta-carbolines from B. caapi vine, the DMT in chacruna leaves is orally inactive due to rapid enzymatic breakdown, making the two-plant combination pharmacologically essential for any effect.
Is chacruna legal to possess or buy?
The legal status of P. viridis varies by country: in the United States, the plant itself occupies a legal grey area, but its primary alkaloid DMT is a Schedule I controlled substance, making possession of the plant for the purpose of DMT extraction potentially illegal. Several countries including Australia and France explicitly list P. viridis as a controlled plant, while others regulate it only when processed; users should verify local law before acquiring the plant.
Does chacruna have any health benefits outside of ayahuasca?
In vitro research shows that P. viridis leaf extracts inhibit acetylcholinesterase by over 90% and exhibit selective cytotoxicity against murine melanoma and breast cancer cell lines at 20–400 µg/mL, while leaving normal cells unharmed. However, these findings come exclusively from cell-based laboratory studies with no animal or human trial data, so no health benefit claims can be made for use of chacruna outside the traditional ayahuasca context.
What are the risks or side effects of taking chacruna?
In an ayahuasca brew, chacruna's DMT content can cause nausea, vomiting, elevated heart rate and blood pressure, intense psychological distress, and acute psychotic episodes in predisposed individuals. The most dangerous risk is serotonin syndrome when combined with SSRIs, SNRIs, MAOIs, or other serotonergic drugs; this combination is potentially fatal and represents an absolute contraindication.
How much DMT does chacruna contain?
DMT concentrations in P. viridis leaves vary considerably depending on geographic origin, plant maturity, and harvest conditions; forensic and phytochemical analyses confirm its presence as the dominant alkaloid, but a universally agreed standardized concentration per gram of dry leaf has not been established in published research. N-methyltryptamine is also present as a secondary indole alkaloid, but it contributes minimally to psychoactivity compared to DMT.
Does chacruna interact with antidepressants or psychiatric medications?
Chacruna contains DMT, which acts on serotonin receptors and may interact with SSRIs, MAOIs, and other psychiatric medications, potentially increasing the risk of serotonin syndrome or reducing medication efficacy. Anyone taking psychiatric medications should consult a healthcare provider before consuming chacruna or ayahuasca preparations. The interaction risk is particularly significant with MAOIs, which are often combined with chacruna-containing brews in traditional ayahuasca ceremonies.
Is chacruna safe for people with heart conditions or high blood pressure?
Chacruna use carries potential cardiovascular risks due to DMT's sympathomimetic effects and the additional cardiovascular stress from ayahuasca preparations, which may increase heart rate and blood pressure. Individuals with pre-existing hypertension, coronary artery disease, or arrhythmias should avoid chacruna entirely and consult with a cardiologist before considering use. Limited clinical data exists on chacruna's isolated cardiovascular effects, but case reports suggest elevated risk in vulnerable populations.
What clinical research exists on chacruna's therapeutic potential for mental health conditions?
Observational studies and preliminary research on ayahuasca (which includes chacruna) suggest potential benefits for treatment-resistant depression and anxiety, though chacruna has not been studied as an isolated therapeutic agent in rigorous clinical trials. Most evidence comes from qualitative studies and case reports rather than randomized controlled trials, limiting conclusions about efficacy and safety. The psychoactive DMT component is the presumed active mechanism, but the therapeutic role of chacruna's other alkaloids and plant constituents remains largely unexamined in human studies.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w chacruna-psychotria-viridis curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
